International and Global Health — MCQs

Q: A community health analysis shows Region A has higher crude mortality rate than Region B, but age-standardized mortality rate is lower in Region A. What is the most likely explanation?

Region A has older population structure. ### Region A has older population structure - A higher **crude mortality rate** in a region often reflects an **older population**, as the absolute number of deaths is naturally higher in older cohorts regardless of specific health risks. - **Age-standardization** removes the confounding effect of age distribution, revealing that if Region A had the same age structure as the standard population, its mortality risk would actually be lower than Region B. *Data collection error in Region B* - While system errors can occur, the scenario describes a classic epidemiological pattern of **confounding by age**, which is the primary reason for calculating **standardized rates**. - There is no statistical or clinical evidence provided to suggest a **systematic data collection error** over a structural demographic difference. *Region B has younger population structure* - If Region B had a younger population, its **crude mortality rate** would likely be lower than Region A's, which is consistent with the data, but it does not explain why Region A's **age-standardized rate** is lower. - This option reverses the logic; the lower standardized rate in Region A implies that its high crude rate is due to its **aged structure**, not Region B's youth. *Region A has better healthcare facilities* - While better healthcare contributes to a lower **standardized mortality rate**, it does not explain the discrepancy between coarse and standardized rates without mentioning **demographics**. - The core of the question tests the understanding of **demographic confounding**; healthcare quality is an outcome, while age structure is the confounding variable being adjusted for.

Q: A 40-year-old man returns from rural Cambodia with fever and severe thrombocytopenia (platelet count 15,000/μL). Peripheral smear shows ring forms with multiple infections per RBC and appliqué forms. Rapid diagnostic test is positive for Plasmodium falciparum HRP2. What is the most appropriate first-line treatment?

Intravenous artesunate. ***Intravenous artesunate*** - This patient presents with **severe malaria** criteria, indicated by a very low platelet count and high-density **Plasmodium falciparum** infection with characteristic **appliqué forms** and multiple ring forms per RBC [1]. - **Intravenous artesunate** is the drug of choice for severe malaria globally as it reduces mortality more effectively than quinine, even in Southeast Asian regions with emerging resistance [1]. *Oral artemether-lumefantrine* - While effective for **uncomplicated malaria**, oral medications are inappropriate for cases showing signs of severity like **severe thrombocytopenia** or high parasitemia [2]. - Patients with severe malaria require parenteral therapy to ensure rapid drug levels and because they may not tolerate oral intake [1]. *Chloroquine with primaquine* - This combination is ineffective here because **Plasmodium falciparum** in Cambodia is highly resistant to **chloroquine** [3]. - **Primaquine** is primarily used to eradicate **hypnozoites** in P. vivax and P. ovale infections, which are not the cause of this patient's acute severe presentation [2]. *Intravenous quinine with doxycycline* - **Intravenous quinine** was previously the standard of care but has been superseded by artesunate due to its higher toxicity and inferior survival outcomes [1]. - Quinine is associated with significant side effects such as **cinchonism** and **hypoglycemia**, making it a second-line option when artesunate is unavailable [2].

Q: What is the target hemoglobin threshold for blood transfusion in severe malaria according to WHO guidelines?

Less than 5 g/dL. Less than 5 g/dL - According to WHO guidelines, blood transfusion is indicated in severe malaria when the hemoglobin level falls below 5 g/dL or the hematocrit falls below 15%. - This threshold is set to minimize risks of fluid overload and transfusion-borne infections while addressing life-threatening anemia in high-transmission areas. Less than 10 g/dL - A threshold of 10 g/dL is considered too high for transfusion in malaria and would lead to unnecessary resource consumption and risks. [1] - It does not align with the specific management protocols for Plasmodium falciparum related complications. Less than 7 g/dL - While 7 g/dL is a common restrictive transfusion threshold in critically ill patients or general hospital settings, it is not the specific WHO cutoff for malaria. - In stable patients with malaria, monitoring is preferred over transfusion at this level unless respiratory distress or cardiac failure occurs. Less than 9 g/dL - This level does not meet the criteria for severe anemia defining a medical emergency in the context of malaria treatment. - Transfusion at this level is generally discouraged unless there are other significant comorbidities or active, massive hemorrhage.

Q: Which organization publishes the World Malaria Report annually?

World Health Organization. ***World Health Organization*** - The **World Health Organization (WHO)** is the authoritative body that publishes the **World Malaria Report** annually to track global and regional trends [1]. - It provides a comprehensive assessment of **malaria control**, elimination efforts, and targets as outlined in the **Global Technical Strategy for Malaria**. *UNICEF* - While **UNICEF** works extensively on child health and distributing **insecticide-treated nets**, it does not publish the primary annual global malaria status report. - Their malaria efforts focus specifically on **maternal and child health** interventions rather than overarching epidemiological data reporting. *Global Fund* - The **Global Fund** to Fight AIDS, Tuberculosis, and Malaria is primarily a **financing mechanism** that provides grants to countries to combat these diseases. - It relies on **WHO data** and metrics to allocate resources but is not the publisher of the annual global report. *Centers for Disease Control and Prevention* - The **CDC** is a national public health agency of the **United States** that provides technical expertise and conducts research on malaria prevention. - While they contribute to the **President’s Malaria Initiative (PMI)**, they are not responsible for the **World Malaria Report**, which is a UN-agency level publication.

A novel rapid diagnostic test for visceral leishmaniasis shows sensitivity of 85% and specificity of 90% in controlled trials. When deployed in a region with 2% prevalence of VL (as determined by gold standard testing), public health officials note that most positive results are false positives. Evaluate the most appropriate strategy to improve the program's effectiveness.

A low-income country plans to introduce HPV vaccination for cervical cancer prevention but faces budget constraints. Current cervical cancer screening coverage is 15% with VIA (Visual Inspection with Acetic acid). Competing priority is expanding TB-DOTS coverage from 60% to 85%. Using WHO principles of priority setting in resource-limited settings, evaluate the best approach.

A country implements universal salt iodization but continues to have high rates of goiter in mountainous regions. Urinary iodine excretion is adequate. Thyroid function tests show normal TSH but low T4 in affected individuals. Analysis of local diet reveals high consumption of cassava and cabbage. What is the most likely mechanism of persistent goiter?

A community health analysis shows Region A has higher crude mortality rate than Region B, but age-standardized mortality rate is lower in Region A. What is the most likely explanation?

A 40-year-old man returns from rural Cambodia with fever and severe thrombocytopenia (platelet count 15,000/μL). Peripheral smear shows ring forms with multiple infections per RBC and appliqué forms. Rapid diagnostic test is positive for Plasmodium falciparum HRP2. What is the most appropriate first-line treatment?

A 35-year-old healthcare worker from India is posted to a sub-Saharan African country for WHO work. She has never had yellow fever. What is the most appropriate vaccination strategy?

How does the Demographic and Epidemiological Transition model explain the shift in disease burden in developing countries?

Why does artemisinin-based combination therapy (ACT) reduce transmission of malaria more effectively than monotherapy?

What is the target hemoglobin threshold for blood transfusion in severe malaria according to WHO guidelines?

Q10

Which organization publishes the World Malaria Report annually?

International and Global Health Indian Medical PG Practice Questions and MCQs

Question 1: A novel rapid diagnostic test for visceral leishmaniasis shows sensitivity of 85% and specificity of 90% in controlled trials. When deployed in a region with 2% prevalence of VL (as determined by gold standard testing), public health officials note that most positive results are false positives. Evaluate the most appropriate strategy to improve the program's effectiveness.

A. Abandon the rapid test and use only microscopy
B. Use the test only in symptomatic patients with high pre-test probability (Correct Answer)
C. Implement two-tier testing with confirmatory parasitological diagnosis for all RDT positives
D. Lower the diagnostic threshold to increase sensitivity

Explanation: ### Use the test only in symptomatic patients with high pre-test probability - In a **low-prevalence** setting (2%), the **positive predictive value (PPV)** is inherently low despite high specificity, leading to a high number of **false positives** [1]. - Restricting the test to those with clinical suspicion (e.g., splenomegaly, prolonged fever) increases the **pre-test probability**, which significantly improves the PPV and program efficiency [2], [3]. ### Abandon the rapid test and use only microscopy - Microscopy (e.g., splenic or bone marrow aspirates) is **invasive**, technically demanding, and often impractical for large-scale field use in poor regions. - Rapid tests are essential for **point-of-care** diagnostics; the issue is not the test's utility but its application in a low-prevalence population. ### Implement two-tier testing with confirmatory parasitological diagnosis for all RDT positives - While this improves accuracy, parasitological confirmation is highly **labor-intensive** and requires **invasive procedures** that are difficult to scale in a public health program. - It does not address the underlying inefficiency of testing low-risk individuals, which wastes resources before the confirmatory step is even reached. ### Lower the diagnostic threshold to increase sensitivity - Lowering the threshold would increase the number of **false positives** because sensitivity and specificity are inversely related [1]. - In this scenario, the primary goal is to improve **specificity/PPV** to reduce false positives, not to find more potentially negative cases by increasing sensitivity.

Question 2: A low-income country plans to introduce HPV vaccination for cervical cancer prevention but faces budget constraints. Current cervical cancer screening coverage is 15% with VIA (Visual Inspection with Acetic acid). Competing priority is expanding TB-DOTS coverage from 60% to 85%. Using WHO principles of priority setting in resource-limited settings, evaluate the best approach.

A. Expand TB-DOTS coverage first due to immediate mortality impact and higher baseline coverage (Correct Answer)
B. Prioritize HPV vaccination as it provides long-term prevention
C. Focus on improving VIA screening coverage instead of vaccination
D. Implement both programs equally with 50% budget allocation each

Explanation: ***Expand TB-DOTS coverage first due to immediate mortality impact and higher baseline coverage*** - According to **WHO priority-setting principles**, interventions for high-mortality infectious diseases like **Tuberculosis** typically take precedence due to immediate impact on life expectancy. [1] - Expanding an existing, successful program from **60% to 85%** is more cost-effective and feasible than initiating new high-cost long-term interventions like **HPV vaccination** in resource-limited settings. [1] *Prioritize HPV vaccination as it provides long-term prevention* - **HPV vaccination** yields benefits only after decades; in constrained budgets, programs addressing **immediate disease burden** are prioritized. - The high **initial cost** and logistical requirements for refrigeration and multi-dose delivery often make it secondary to fundamental public health needs. *Focus on improving VIA screening coverage instead of vaccination* - While **VIA (Visual Inspection with Acetic acid)** is low-cost, improving it from a low **15% baseline** does not address the high mortality risk associated with **TB outbreaks**. - Screening programs require robust **linking to treatment centers**, which may not be as well-established as the existing **TB-DOTS infrastructure**. *Implement both programs equally with 50% budget allocation each* - An equal **50% budget allocation** ignores the principle of **marginal cost-effectiveness**, where underfunding two programs may lead to both being ineffective. - **WHO principles** advocate for focusing resources on the **burden of disease** and existing capacity rather than arbitrary split funding.

Question 3: A country implements universal salt iodization but continues to have high rates of goiter in mountainous regions. Urinary iodine excretion is adequate. Thyroid function tests show normal TSH but low T4 in affected individuals. Analysis of local diet reveals high consumption of cassava and cabbage. What is the most likely mechanism of persistent goiter?

A. Genetic resistance to iodine supplementation
B. Goitrogenic effect of thiocyanates interfering with iodine uptake (Correct Answer)
C. Inadequate iodine absorption due to altitude
D. Selenium deficiency preventing T4 to T3 conversion

Explanation: ***Goitrogenic effect of thiocyanates interfering with iodine uptake*** - **Cassava** and **cabbage** contain cyanogenic glucosides and glucosinolates that are metabolized into **thiocyanates**, which competitively inhibit the **sodium-iodide symporter (NIS)**. - This leads to a **secondary iodine deficiency** at the follicular cell level, causing thyroid enlargement (**goiter**) despite adequate systemic iodine levels as reflected by normal **urinary iodine excretion**. *Genetic resistance to iodine supplementation* - While mutations in the **NIS** or **thyroglobulin genes** can cause congenital hypothyroidism, they typically result in **elevated TSH** and would not be specific to a regional diet. - Population-wide genetic resistance is unlikely to be the primary cause of a localized outbreak linked to specific **dietary habits**. *Inadequate iodine absorption due to altitude* - **Altitude** does not biologically impair the absorption of iodine in the **gastrointestinal tract**. - Mountainous regions historically have goiter due to **iodine-depleted soil**, but this is excluded here since the scenario states **universal salt iodization** and adequate **urinary iodine**. *Selenium deficiency preventing T4 to T3 conversion* - **Selenium** is a cofactor for **deiodinase enzymes**; a deficiency would typically result in **low T3** and **normal or high T4** levels. - This mechanism does not explain the **low T4** and presence of goiter when iodine intake is biochemically confirmed to be sufficient [1].

Question 4: A community health analysis shows Region A has higher crude mortality rate than Region B, but age-standardized mortality rate is lower in Region A. What is the most likely explanation?

A. Data collection error in Region B
B. Region B has younger population structure
C. Region A has older population structure (Correct Answer)
D. Region A has better healthcare facilities

Explanation: ### Region A has older population structure - A higher **crude mortality rate** in a region often reflects an **older population**, as the absolute number of deaths is naturally higher in older cohorts regardless of specific health risks. - **Age-standardization** removes the confounding effect of age distribution, revealing that if Region A had the same age structure as the standard population, its mortality risk would actually be lower than Region B. *Data collection error in Region B* - While system errors can occur, the scenario describes a classic epidemiological pattern of **confounding by age**, which is the primary reason for calculating **standardized rates**. - There is no statistical or clinical evidence provided to suggest a **systematic data collection error** over a structural demographic difference. *Region B has younger population structure* - If Region B had a younger population, its **crude mortality rate** would likely be lower than Region A's, which is consistent with the data, but it does not explain why Region A's **age-standardized rate** is lower. - This option reverses the logic; the lower standardized rate in Region A implies that its high crude rate is due to its **aged structure**, not Region B's youth. *Region A has better healthcare facilities* - While better healthcare contributes to a lower **standardized mortality rate**, it does not explain the discrepancy between coarse and standardized rates without mentioning **demographics**. - The core of the question tests the understanding of **demographic confounding**; healthcare quality is an outcome, while age structure is the confounding variable being adjusted for.

Question 5: A 40-year-old man returns from rural Cambodia with fever and severe thrombocytopenia (platelet count 15,000/μL). Peripheral smear shows ring forms with multiple infections per RBC and appliqué forms. Rapid diagnostic test is positive for Plasmodium falciparum HRP2. What is the most appropriate first-line treatment?

A. Oral artemether-lumefantrine
B. Chloroquine with primaquine
C. Intravenous artesunate (Correct Answer)
D. Intravenous quinine with doxycycline

Explanation: ***Intravenous artesunate*** - This patient presents with **severe malaria** criteria, indicated by a very low platelet count and high-density **Plasmodium falciparum** infection with characteristic **appliqué forms** and multiple ring forms per RBC [1]. - **Intravenous artesunate** is the drug of choice for severe malaria globally as it reduces mortality more effectively than quinine, even in Southeast Asian regions with emerging resistance [1]. *Oral artemether-lumefantrine* - While effective for **uncomplicated malaria**, oral medications are inappropriate for cases showing signs of severity like **severe thrombocytopenia** or high parasitemia [2]. - Patients with severe malaria require parenteral therapy to ensure rapid drug levels and because they may not tolerate oral intake [1]. *Chloroquine with primaquine* - This combination is ineffective here because **Plasmodium falciparum** in Cambodia is highly resistant to **chloroquine** [3]. - **Primaquine** is primarily used to eradicate **hypnozoites** in P. vivax and P. ovale infections, which are not the cause of this patient's acute severe presentation [2]. *Intravenous quinine with doxycycline* - **Intravenous quinine** was previously the standard of care but has been superseded by artesunate due to its higher toxicity and inferior survival outcomes [1]. - Quinine is associated with significant side effects such as **cinchonism** and **hypoglycemia**, making it a second-line option when artesunate is unavailable [2].

Question 6: A 35-year-old healthcare worker from India is posted to a sub-Saharan African country for WHO work. She has never had yellow fever. What is the most appropriate vaccination strategy?

A. Two doses of yellow fever vaccine 4 weeks apart
B. Single dose of yellow fever vaccine at least 10 days before travel (Correct Answer)
C. Yellow fever immunoglobulin followed by vaccine
D. Yellow fever vaccine with booster after 10 years

Explanation: ***Single dose of yellow fever vaccine at least 10 days before travel*** - A **single primary dose** of the **17D live-attenuated vaccine** is sufficient to confer **lifelong immunity** in most healthy travelers. - The vaccine must be administered at least **10 days prior** to arrival in an endemic area for the **International Certificate of Vaccination** to be valid and for protective immunity to develop. *Two doses of yellow fever vaccine 4 weeks apart* - Unlike some other vaccines, the yellow fever vaccine does not require a **two-dose primary series** for immunocompetent individuals. - A single dose results in **seroconversion** in over 99% of recipients within 30 days. *Yellow fever immunoglobulin followed by vaccine* - **Passive immunization** with immunoglobulins is not a standard clinical practice for yellow fever prevention. - Pre-exposure prophylaxis relies solely on the **live-attenuated vaccine** to trigger an active immune response. *Yellow fever vaccine with booster after 10 years* - According to **WHO guidelines** updated in 2016, a **booster dose** every 10 years is no longer required for international travel [1]. - While certain **immunocompromised groups** or high-risk lab workers might be considered for boosters, it is not recommended for the general healthcare traveler [1].

Question 7: How does the Demographic and Epidemiological Transition model explain the shift in disease burden in developing countries?

A. NCDs completely replace infectious diseases
B. Double burden emerges with persistence of infectious diseases alongside rising NCDs (Correct Answer)
C. Infectious diseases remain constant while NCDs increase
D. Mental health disorders become the primary burden

Explanation: ***Double burden emerges with persistence of infectious diseases alongside rising NCDs*** - Developing countries undergo a transition where **non-communicable diseases (NCDs)** rise due to urbanization and aging, while **infectious diseases** remain prevalent due to poor sanitation [1]. - This creates a **double burden of disease**, complicating public health strategies as resources must be allocated to both acute infections and chronic conditions. *NCDs completely replace infectious diseases* - This scenario describes a **completed epidemiological transition**, which is more characteristic of developed, high-income nations [1]. - In developing nations, the transition is often **protracted**, meaning infectious diseases do not fully disappear before NCDs become dominant. *Infectious diseases remain constant while NCDs increase* - Epidemiological transition typically exhibits a **decline in infectious disease** frequency as primary care and vaccinations improve, even if they aren't eradicated [1]. - A static rate of infection is not part of the model; rather, there is a **shift in the proportional profile** of morbidity and mortality. *Mental health disorders become the primary burden* - While **mental health disorders** contribute significantly to the Global Burden of Disease (GBD), they are generally categorized under NCDs rather than being a separate phase of transition. - The model specifically focuses on the handover from **communicable diseases** to **degenerative/man-made diseases**, not the absolute dominance of psychiatric illness.

Question 8: Why does artemisinin-based combination therapy (ACT) reduce transmission of malaria more effectively than monotherapy?

A. It directly inhibits mosquito midgut development
B. It prevents sequestration of parasites
C. It achieves faster parasite clearance reducing gametocyte production (Correct Answer)
D. It kills gametocytes more rapidly

Explanation: ### It achieves faster parasite clearance reducing gametocyte production - **Artemisinin derivatives** provide rapid reduction of the total **parasite biomass**, which significantly limits the pool available to differentiate into **gametocytes** [1]. - By killing the asexual stages faster than other drugs, **ACT** prevents the subsequent wave of **infectivity** required for transmission back to the mosquito host [1]. ### It directly inhibits mosquito midgut development - **Artemisinin** does not interact with the biological processes of the **Anopheles mosquito** vector directly. - Transmission reduction is a result of **parasite suppression** in the human host, not an **insecticidal** or developmental effect on the vector. ### It prevents sequestration of parasites - While **Artemisinins** affect all erythrocytic stages, the primary mechanism of transmission control is the **rapid clearance** of the infection rather than specifically preventing **sequestration**. - Sequestration is more closely linked to the **pathogenesis of severe malaria** (e.g., cerebral malaria) than to the direct reduction of population-level transmission. ### It kills gametocytes more rapidly - Although **Artemisinins** are effective against **early stage (I-IV)** gametocytes, they have limited activity against the **mature stage V gametocytes** of *P. falciparum* [1]. - The primary driver for reduced transmission is the **prevention** of gametocyte formation via rapid **asexual stage clearance** rather than a specific gametocidal action on mature forms [1].

Question 9: What is the target hemoglobin threshold for blood transfusion in severe malaria according to WHO guidelines?

A. Less than 5 g/dL (Correct Answer)
B. Less than 10 g/dL
C. Less than 7 g/dL
D. Less than 9 g/dL

Explanation: Less than 5 g/dL - According to WHO guidelines, blood transfusion is indicated in severe malaria when the hemoglobin level falls below 5 g/dL or the hematocrit falls below 15%. - This threshold is set to minimize risks of fluid overload and transfusion-borne infections while addressing life-threatening anemia in high-transmission areas. Less than 10 g/dL - A threshold of 10 g/dL is considered too high for transfusion in malaria and would lead to unnecessary resource consumption and risks. [1] - It does not align with the specific management protocols for Plasmodium falciparum related complications. Less than 7 g/dL - While 7 g/dL is a common restrictive transfusion threshold in critically ill patients or general hospital settings, it is not the specific WHO cutoff for malaria. - In stable patients with malaria, monitoring is preferred over transfusion at this level unless respiratory distress or cardiac failure occurs. Less than 9 g/dL - This level does not meet the criteria for severe anemia defining a medical emergency in the context of malaria treatment. - Transfusion at this level is generally discouraged unless there are other significant comorbidities or active, massive hemorrhage.

Question 10: Which organization publishes the World Malaria Report annually?

A. World Health Organization (Correct Answer)
B. UNICEF
C. Global Fund
D. Centers for Disease Control and Prevention

Explanation: ***World Health Organization*** - The **World Health Organization (WHO)** is the authoritative body that publishes the **World Malaria Report** annually to track global and regional trends [1]. - It provides a comprehensive assessment of **malaria control**, elimination efforts, and targets as outlined in the **Global Technical Strategy for Malaria**. *UNICEF* - While **UNICEF** works extensively on child health and distributing **insecticide-treated nets**, it does not publish the primary annual global malaria status report. - Their malaria efforts focus specifically on **maternal and child health** interventions rather than overarching epidemiological data reporting. *Global Fund* - The **Global Fund** to Fight AIDS, Tuberculosis, and Malaria is primarily a **financing mechanism** that provides grants to countries to combat these diseases. - It relies on **WHO data** and metrics to allocate resources but is not the publisher of the annual global report. *Centers for Disease Control and Prevention* - The **CDC** is a national public health agency of the **United States** that provides technical expertise and conducts research on malaria prevention. - While they contribute to the **President’s Malaria Initiative (PMI)**, they are not responsible for the **World Malaria Report**, which is a UN-agency level publication.

Practice by Chapter

Global Burden of Disease

Practice Questions

Health Systems Strengthening

Practice Questions

Tropical Medicine

Practice Questions

Neglected Tropical Diseases

Practice Questions

Global Infectious Disease Control

Practice Questions

Non-communicable Diseases Globally

Practice Questions

Maternal and Child Health Worldwide

Practice Questions

Global Health Ethics

Practice Questions

Health and Human Rights

Practice Questions

Migration and Refugee Health

Practice Questions

International Health Regulations

Practice Questions

Global Health Security

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free